Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
01:00pm, Friday, 25'th Apr 2025
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
06:00am, Monday, 21'st Apr 2025
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
06:00am, Thursday, 17'th Apr 2025
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Insiders Make Huge Purchases of These 4 Biotech Stocks
08:40am, Wednesday, 26'th Mar 2025
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 26'th Mar 2025
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
04:30pm, Tuesday, 25'th Mar 2025
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile
Huge Insider Buying: Victoria's Secret, Carl Icahn, and More
08:45am, Saturday, 15'th Mar 2025
Despite (or perhaps because of) the volatility in the stock market and uncertainty about the economy, insiders are still scooping up shares of certain stocks.
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
01:18pm, Thursday, 06'th Mar 2025
On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
08:43pm, Wednesday, 05'th Mar 2025
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President,
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
06:16pm, Wednesday, 05'th Mar 2025
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago.
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Wednesday, 05'th Mar 2025
VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
06:00am, Wednesday, 26'th Feb 2025
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 25'th Feb 2025
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
06:00am, Tuesday, 18'th Feb 2025
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
06:00am, Thursday, 13'th Feb 2025
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
